{
  "ticker": "CU6",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975974",
  "id": "02975974",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250801",
  "time": "1459",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mfnbttfwtly6.pdf",
  "summary": "- **Substantial Holder Change**: Alan John Taylor and associates ceased to be substantial holders in Clarity Pharmaceuticals on **1 August 2025**.  \n- **Reason**: Dilution from a **Placement** announced on **28 July 2025**, reducing holdings by **2,219,151** (Alan Taylor), **13,266,660** (Taylor Family Trust), and **800,000** (Sally Taylor) shares.  \n\n*Note: No further material capital markets impact beyond the dilution-driven cessation of substantial holdings.*",
  "usage": {
    "prompt_tokens": 1433,
    "completion_tokens": 111,
    "total_tokens": 1544,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-01T05:58:18.568757"
}